ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and T2 Biosystems (NASDAQ:TTOO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Insider & Institutional Ownership
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for ClearPoint Neuro and T2 Biosystems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ClearPoint Neuro | 0 | 0 | 3 | 0 | 3.00 |
| T2 Biosystems | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares ClearPoint Neuro and T2 Biosystems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ClearPoint Neuro | -64.51% | -78.09% | -51.33% |
| T2 Biosystems | -563.16% | N/A | -174.06% |
Risk & Volatility
ClearPoint Neuro has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Earnings and Valuation
This table compares ClearPoint Neuro and T2 Biosystems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ClearPoint Neuro | $31.39 million | 9.96 | -$18.91 million | ($0.76) | -14.70 |
| T2 Biosystems | $7.68 million | 0.36 | -$50.08 million | N/A | N/A |
ClearPoint Neuro has higher revenue and earnings than T2 Biosystems.
Summary
ClearPoint Neuro beats T2 Biosystems on 10 of the 12 factors compared between the two stocks.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
About T2 Biosystems
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
